EGFR and lung cancer: Pathways of driver mutated genes are highly lung cancer-related pathways such as Non-small-cell lung cancer, EGFR tyrosine kinase inhibitor resistance, Platinum drug resistance, MAPK signaling and Ras signaling (Figure 10C,D) and other immunologic and metabolic pathways such as FoxO signaling pathway, Central carbon metabolism in cancer, Proteoglycans in cancer, Hepatitis B, Hepatitis C, PD-L1 expression and PD-1 checkpoint pathway in cancer for both risk groups.